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Usefulness of NT-proBNP serum level in the diagnosis of dyspnea
in COPD patients
Przydatność oznaczania NT-proBNP w diagnostyce duszności
u chorych na POChP
Results of this study are the part of NCBR project "Chronic obstructive pulmonary disease (COPD) — systemic disease, the
biggest threat of XXI century”. All the study subjects signed an  informed consent. The study was approved by the Bioethical
Committee of the Medical University of Warsaw.
Abstract
Introduction. Cardiovascular diseases often coexist with chronic obstructive pulmonary disease (COPD), and in some cases
it is difficult to differentiate between cardiac and pulmonary cause of dyspnoea. It is well known that the serum concentra-
tion of NT-proBNP in patients with cardiovascular diseases, especially with congestive heart failure, is elevated. The aim of
this study was to estimate the usefulness of NT-proBNP serum level measurement in patients with COPD complaining of
chronic dyspnoea.
Material and methods. The study group consisted of 81 stable COPD patients in the mean age, 65 ± 7 years, (57 of them with
concomitant cardiovascular disease). Serum concentration of NT-proBNP was measured using VITROS laboratory test.
Results. There were no statistical differences in serum NT-proBNP between patients stratified according to the GOLD staging
system for COPD severity or BODE index and mMRC breathlessness scale. The concentration of NT-proBNP was statistically
significantly higher in the patients with coexisting cardiovascular diseases (220.8 ± 258.1 vs. 95.4±56.1 pg/ml). The group of
patients with NT-proBNP concentration > 125 pg/ml (n = 36) was statistically significantly older (67.5 ± 6 years old vs. 63.2 ±
7.1 years old; p = 0.009) and had statistically significantly lower PaO2 (67.4 ± 11.8 mm Hg vs. 73.0 ± 11.6 mm Hg; p = 0.04).
Conclusions. 1. In the group of stable COPD patients there were no differences between NT-proBNP serum concentration
according to GOLD staging, BODE index, and mMRC breathlessness scale. 2. The NT-proBNP serum concentration was
statistically significantly higher in the group of COPD patients with the concomitant cardiovascular disease. 3. In patients
with chronic dyspnoea testing of serum NT-proBNP may be useful in the detection of patients with cardiovascular problems,
who require more intensive therapy.
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Introduction
According to the Global Initiative for Chronic
Obstructive Lung Disease (GOLD), patients with
chronic obstructive lung disease (COPD) are at hi-
gher risk for cardiovascular diseases, which is a
result of general inflammatory process [1]. Establi-
shing the cause of breathlessness in patients with
COPD may be challenging as symptoms of COPD
and heart failure are similar. Some tests, such as:
spirometry, chest X-ray, and echocardiogram may
be useful, but they require specialistic equipment,
that is not always available. A laboratory test that
may be helpful in the process of investigating the
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cause of breathlessness is the measurement of
N-terminal fragment of natriuretic peptide
(NT-proBNP) serum level.
The natriuretic peptides (atrial natriuretic pep-
tide — ANP and brain natriuretic peptide — BNP) are
neurohormones. They play a role in the regulation
of the water and sodium balance, and in the home-
ostasis of the cardiovascular system [2]. Natriuretic
peptides are released by cardiomyocytes as a respon-
se to stretching. They reduce the secretion of rennin
and aldosterone, inhibit the activity of the adrener-
gic nervous system, augment urine volume and so-
dium excretion, and have a direct vasodilating effect.
An increase in NT-proBNP blood level is a result of
activation of compensatory mechanisms before cli-
nical features of heart failure develop [3]. High le-
vels of NT-proBNP have also been observed in atrial
fibrillation [4], left ventricle hypertrophy [5], and
pulmonary hypertension [6]. Many authors have re-
ported on the usefulness of NT-proBNP in acute dys-
pnoea [7]. The aim of our study was the evaluation
of the usefulness of NT-proBNP in patients with sta-
ble COPD complaining of chronic breathlessness.
Materials and methods
Subsequent COPD patients from the Chest
Outpatient Clinic in the Public Central Teaching
Hospital of the Medical University in Warsaw were
recruited in the study. The diagnosis of COPD was
established on the basis of typical symptoms and
spirometry, in accordance with the Polish Society
of Lung Diseases (PTChP) guidelines [8]. The exc-
lusion criteria were: respiratory tract infection or
symptoms suggesting COPD exacerbation in the
preceding month. Due to these criteria around 5%
of the initially recruited patients were ultimately
excluded from the study.
A medical history, with special attention paid
to concomitant cardiovascular conditions, was ta-
ken from all patients and a physical examination
was performed. The results of additional tests
(chest X-ray) and discharge letters from the past
were also analysed. The following tests were per-
formed: spirometry and plethysmography with re-
versibility test (LungTest 1000Spirometer, MES,
Poland; Vmax 6200 Sensormedics Plethysmo-
graph, Yorba Linda, USA) according to PTChP gu-
idelines [9], and the assessment of diffusing capa-
city of the lungs for carbon monoxide (DLCO) (n
= 30). Six-minute walk test (6MWT) was perfor-
med in 77 patients; guidelines of the American
Thoracic Society (ATS) were applied [10]. The
degree of dyspnoea was assessed using the Medi-
cal Research Council (MRC) scale [11].
For the purposes of statistical analyses the stu-
died population was divided in 2 groups: group A
— without concomitant cardiovascular diseases,
and group B — with concomitant circulatory sys-
tem diseases. In addition, 4 stages of COPD severi-
ty according to GOLD 2010 guidelines were distin-
guished. Based on BODE (body mass index, airflow
obstruction, dyspnoea, exercise capacity) index [12]
patients were allocated to one of four quartiles: 1 —
BODE index £ 2, 2 — BODE index 3–4, 3 — BODE
index 5–6, and 4 — BODE index ≥ 7.
VITROS NT-proBNP Reagent Pack and VI-
TROS NT-proBNP calibrators were used to measu-
re serum levels of NT-proBNP. A sample of peri-
pheral venous blood (5 ml) was taken from the
patients. The upper limit of normal for NT-proBNP
level in patients younger than 75 years of age was
established following the manufacturer’s recom-
mendations at 125 pg/ml. According to information
provided by the manufacturer of the reagent, the
sensitivity and specificity of the test were, respec-
tively: 89.5% and 84.1% for men, and 94.9% and
75% for women. Depending on the NT-proBNP
blood level, two groups in the studied population
were distinguished: with normal (£ 125 pg/ml) and
with elevated (> 125 pg/ml) NT-proBNP levels.
Arterial blood gases analysis, in room air, was
also performed.
Statistical analyses
All analyses were performed using STATISTI-
CA v.10 (StatSoft, Inc, 2011; www.statsoft.com) com-
puter software. Results were expressed as the mean
values ± standard deviation, the number of patients
in a sample, and the percentage of studied popula-
tions it constitutes, as shown in the tables. Most of
the variables did not have a normal distribution; the-
refore, U Mann-Whitney test and ANOVA Kruskal-
Wallis test were used for comparisons between the
groups. Correlations between parameters were chec-
ked with Spearman’s correlation coefficient. P<0.05
was considered statistically significant.
Results
Eighty-one COPD patients were enrolled into
the study (35 women, 46 men), all of them youn-
ger than 75 years of age (mean age 65 ± 7 years).
At the time of recruitment 55 patients were treated
for arterial hypertension, ischaemic heart disease,
or chronic heart insufficiency; 16 patients had
oxygen concentrators at home. The following gro-
ups of medications were used in the group of pa-
tients with cardiovascular diseases: angiotensin-
converting enzyme inhibitors (n = 36), beta-adrenocep-
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Table 2. NT-proBNP concentration according to sex. concomitant cardiovascular disease. GOLD 2010 staging system for
COPD severity and BODE index
N NT-proBNP [pg/ml] p
All study group 81 189.8 ± 234.1
Men 46 194.2 ± 257.6
Women 35 169.4 ± 134.2 NS
Patients without cardiovascular disease (A) 26 95.4 ± 56.1
Patients with cardiovascular disease (B) 55 220.8 ± 258.1 0.03
GOLD 1 14 113.6 ± 123.6
GOLD 2 25 232.2 ± 307.8
GOLD 3 20 154.6 ± 152.1 NS
GOLD 4 22 230.8 ± 253.6
BODE 1 (0–2) 22 198.6 ± 327.2
BODE 2 (2–3) 29 168.2 ± 144.7
BODE 3 (4–5) 15 188.5 ± 164.8 NS
BODE 4 (≥ 7) 11 205.5 ± 198.6
tor blockers (n = 29), diuretics (n = 21), statins (n =
26), calcium channel blockers (n = 18), and digitalis
(n = 2). The full characteristics of the studied group
are presented in Table 1. All degrees of COPD severity
(according to GOLD 2010) and whole BODE index range
were represented in the studied group (Tab. 2).
There were no significant differences in NT-
proBNP levels depending on the COPD severity,
BODE index quartile, or scores in MRC scale. Sta-
tistically significant differences in NT-proBNP le-
vels were, however, found between groups A and
B (95.4 ± 56.1 vs. 220.8 ± 258.1 pg/ml, p = 0.03)
(Tab. 2). There were no differences between gro-
ups A and B in respect to pulmonary function te-
sts, but there was a difference in 6MWT distance
486.9 ± 129.1 m vs. 394.7 m ± 119.0, respective-
ly; p = 0.003) — Table 3. There were no signifi-
cant relationships between NT-proBNP levels and
degree of oxygen desaturation during 6MWT,
either. Mean DLCO for 30 patients (13 patients with
normal NT-proBNP levels and 17 patients with ele-
vated NT-proBNP levels) was 63.5 ± 28.3% of pre-
dicted value. Groups A and B, as well as patients
with normal and elevated levels of NT-proBNP, did
not differ in regard to DLCO. There was no corre-
lation between DLCO (expressed in actual values,
percentage of predicted value, or corrected for the
alveolar volume) and NT-proBNP levels, either. Pa-
tients with NT-proBNP > 125 pg/ml (n = 36) were
significantly older (67.5 ± 6.0 vs. 63.2 ±7.1 years;
p = 0.009) and had significantly lower PaO2 (67.4
±11.8 vs. 73.0 ± 11.6 mmHg; p = 0.04) in compa-
rison to patients with normal NT-proBNP levels.
Both groups had similar smoking history and body
mass index (BMI). There were no significant diffe-
rences in cardio-vascular medications (angioten-
sin-converting enzyme inhibitors, beta-adrenocep-
tor blockers, diuretics, statins, calcium channel
blockers, digitalis) or respiratory medications
(short- and long-acting beta agonists, anticholiner-
gic agents, methylxantines, inhaled corticostero-
ids) between these two groups.
Table 1. Characteristics of study group
All patients Patients without Patients with p
cardiovascular disease (A) cardiovascular disease (B)
N 81 26 55
Age (years) 65 ± 7 62,7 ± 7,3 65,8 ± 6,6 0,009
Number of smoke pack/years 41 ± 20,1 44,9 ± 24,5 40,0 ± 18,7 NS
BMI [kg/m2] 27,3 ± 5,3 26,0 ± 5,0 28 ± 5,4 NS
Home oxygen therapy n (%) 16 (20) 3 (13) 16 (29,1) NS
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Table 3. Results of the lung function tests and 6MWT
All patients Group A Group B p
N 81 25 56
FEV1 % pred. 52.3 ± 17.1 53.6 ± 20.7 47.6 ± 16.5 NS
FVC % pred. 83.2 ± 19.01 84.7 ± 23.1 80.2 ± 21.05 NS
TLC % pred. 124.5 ± 21.2 129.5 ± 17 127.9 ± 19.4 NS
RV % pred. 194.1 ± 56.1 203.5 ± 61.7 207.8 ± 54.1 NS
RV% TLC 60.6 ± 9.6 57.4 ± 12.6 62.7 ± 8.9 NS
Salbutamol 400 μg
FEV1 % pred. 58.8 ± 18.6 59.9 ± 23.1 53.4 ± 18.8 NS
FVC % pred. 92.8 ± 19.2 95.4 ± 21.7 88.3 ± 21.8 NS
FEV1%FVC 49.7 ± 11.4 49.6 ± 11.9 48.3 ± 11.3 NS
TLC % pred. 121.8 ± 21.7 128.5 ± 17.8 124.4 ± 20.7 NS
RV % pred. 173.5 ± 52.28 185.3 ± 54.3 187.2 ± 56.3 NS
RV %TLC 55.7 ± 9.6 53.3 ± 12.1 58.3 ± 9.9 NS
6MWT (N) 77 22 55
Distance [m] 433.5 ± 114.2 486.9 ± 129.1 394.7 ± 119.0 0.003
Discussion
The coexistence of COPD and cardiovascular
system diseases has been confirmed by studies and
recommendations of scientific societies [1, 8]. The
results of our research also indicate such a rela-
tionship [13]. Cigarette smoking — the main cau-
se of COPD — carries a 50% increase of heart in-
sufficiency risk [14]. Between 10 and 33% of pa-
tients with heart failure report coexistence of COPD
[15, 16]. The prevalence of COPD in the popula-
tion with heart failure is higher than in the gene-
ral population (20% vs. 13%) [17]. Ivernes et al.
showed the coexistence of these two conditions by
performing spirometry in 532 patients with heart
insufficiency. COPD and heart failure coexisted in
35% of the studied patients, and only 43% of pa-
tients with COPD diagnosed on that occasion knew
about it before. On the other hand, 1/3 of patients
who had claimed to have COPD did not fulfil spi-
rometric criteria for such a diagnosis [18].
The necessity of differentiation between possi-
ble causes of dyspnoea, in the situation when such
a large proportion of patients give incorrect infor-
mation about their medical history, prompts the
search for new, simple diagnostic tools. In the stu-
dy of Morrison et al., among 321 patients admitted
to the emergency department due to acute breath-
lessness, 42 had COPD and 134 had chronic heart
failure. Mean BNP level in COPD patients was 54
± 71 pg/ml, whereas in cardiac patients it was si-
gnificantly higher — 758 ± 798 pg/ml [19]. Other
authors assessed NT-proBNP levels in patients ho-
spitalised due to COPD exacerbation. They found
that factors associated with elevation of NT-proBNP
included atrial fibrillation and age. No influence of
sex and renal function were observed [20]. Fabbian
et al. found elevated levels of NT-proBNP in 68.7%
of elderly patients admitted to a hospital due to bre-
athlessness (in 49.2% of patients with heart failure
and in 20.6% of patients with lung diseases). NT-
proBNP levels were also elevated in patients with
renal insufficiency, low haemoglobin levels and —
similarly as in the study of Sanches-Marteles et al.
— in patients with atrial fibrillation [20, 21].
The aim of our study was to assess the use-
fulness of NT-proBNP blood levels in patients
with stable COPD complaining of chronic breath-
lessness. We did not find any significant diffe-
rences in the levels of this biomarker depending
on COPD severity, BODE index, or dyspnoea me-
asured with MRC scale. The presence of circula-
tory system diseases was the only factor that had
a significant influence on NT-proBNP levels, and
that was compatible with the findings of other
authors. Rutten et al. studied BNP and NT-
proBNP in 200 stable COPD patients above 65
years of age in the context of cardiac and respi-
ratory system function. Similarly to the authors
of the present study, they found no relationship
between the biomarker levels and the severity of
COPD (according to GOLD), and the dependen-
ce of the biomarker levels on heart failure. What
is more, higher levels of both biomarkers were
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found in patients with systolic heart failure in
comparison to patients with isolated diastolic
heart failure [22]. Additionally, the degree of air-
way obstruction had no effect on NT-proBNP
levels in patients with chronic dyspnoea in a stu-
dy by Wieshammer et al. [23].
Remodelling of skeletal muscles is present in
COPD as well as in heart failure. It makes muscles
less efficient. The coexistence of both these con-
ditions increases the likelihood of a poor progno-
sis [24]. Medina et al. investigated the prognostic
value of NT-proBNP in patients admitted to a ho-
spital due to exacerbation of COPD, asthma, or
acute respiratory tract infections (including pneu-
monia). NT-proBNP levels > 587.9 pg/ml correla-
ted with the length of hospitalisation and with
mortality, whereas NT-proBNP levels > 782.2 pg/
ml correlated with the death rate due to cardio-
pulmonary causes during one year of observation
[25]. The other study also showed the usefulness
of this biomarker in early death prediction (within
30 days) in patients admitted to hospital due to
COPD exacerbation [26].
In summary, measurement of NT-proBNP blo-
od levels in patients with dyspnoea and respiratory
system diseases should aim at identification of in-
dividuals with coexisting heart failure, which may
be relevant for prognosis and further treatment.
Conclusions
1. There were no significant differences in NT-
proBNP serum levels between groups depen-
ding on the disease severity or on the BODE
index in the stable stage of COPD.
2. NT-proBNP levels were significantly higher in
patients in whom COPD coexisted with circu-
latory system diseases in comparison to COPD
patients without comorbidities.
3. Measurement of NT-proBNP in patients with
chronic dyspnoea may help with the identifi-
cation of patients in whom therapy for heart
insufficiency should be started or intensified
and in whom further radiologic diagnostic te-
sts should be carried out.
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